Lexaria Bioscience Corp. has reached a significant milestone in its intellectual property strategy, announcing it now holds 60 valid patents granted across major global markets. The company received six new patents since its last update in October 2025, expanding protections for its DehydraTECH drug delivery platform technology.
The new patents strengthen Lexaria's position in several key therapeutic areas. In patent Family #20, focused on compositions and methods for sublingual delivery of nicotine, the company received its first Australian patent, adding to existing protections in the United States, Canada, and Japan. For patent Family #21, addressing compositions and methods for treating hypertension, Lexaria secured its first European Union patent, entering what is considered the world's second-largest hypertension market following the United States.
Lexaria's epilepsy-focused patent Family #24 gained substantial protection with two new Australian patents and one European Union patent, bringing the total to six U.S. patents, four Australian patents, and one European Union patent in this category. The company also strengthened its diabetes portfolio in patent Family #27 with a new U.S. patent, bringing the total to two U.S. patents in this family, which gains importance given recent successes in the GLP-1 sector.
The company's patent strategy follows a rigorous research process, beginning with evaluation of existing scientific literature, followed by animal and human testing to generate supporting data before pursuing patent applications in international markets. Lexaria emphasizes that granted patents provide the security needed to pursue commercial relationships to exploit its innovations.
Lexaria's intellectual property expansion comes as the company prepares for its 2026 Annual Meeting scheduled for January 27, 2026. The company reminds shareholders that those holding common stock at the close of business on December 1, 2025, remain entitled to vote, even if they have since sold their shares. Proxy materials and the annual report are available online at https://www.colonialstock.com/LEXX2026, where shareholders can vote using their control number. The company encourages shareholders to review materials in detail and cast votes before the January 26, 2026, deadline.
The expansion of Lexaria's patent portfolio to 60 granted patents worldwide represents significant validation of the company's DehydraTECH technology, which improves how drugs enter the bloodstream through oral delivery by increasing bio-absorption, reducing side effects, and enhancing delivery across the blood-brain barrier. This intellectual property foundation supports the company's position as a global innovator in drug delivery platforms while providing protection for its research investments across multiple therapeutic areas with substantial market potential.
